| **Author, year** | **Databases and time period covered** | **Number of studiesNumber of patients** | **Characteristics of identified articles: study designs** | **Characteristics of identified articles: populations** | **Characteristics of identified articles: interventions** | **Funding** | **Quality rating** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Ding, 2012101U.S. Food and Drug Administration | International Pharmaceutical Abstracts, Inteleos, Embase, Scopus (searches conducted by U.S. Food and Drug Administration and GlaxoSmithKline)Inception to 2009 | 26 RCTs included in meta-analysisN=9,868 (5,028 ABC vs. 4,840 non-ABC) | Trials, sample size >50(Observational studies excluded) | HIV+ individuals, adults, studies not conducted in Africa ABC vs. non-ABC:*GlaxoSmithKline trials*N: 2,341 vs. 2,367% Male: 78% vs. 76%Age: 36 vs. 37 yearsCD4 count: 360 vs. 360 cells/mm3Log viral load: 4.38 vs. 4.38 log10 copies/mL*AIDS Clinical Trials Group trials*N: 1,985 vs. 1,610% Male: 81% vs. 83%Age: 38 vs. 39 yearsCD4 count: 237 vs. 235 cells/mm3Log viral load: 4.72 vs. 4.7 log10 copies/mL*Other trials*N: 702 vs. 863% Male: 82% vs. 66%Age: 42 vs. 42 yearsCD4 count: 255 vs. 250 cells/mm3Log viral load: 5.03 vs. 4.94 log10 copies/mL | ABC, randomized as part of a combined antiretroviral regimen, vs. non-ABC regimens | Reports no funding or conflicts of interest | Fair |
| Ford, 2015105 | MEDLINE, Embase, LILACS, Cochrane Central Register of Controlled TrialsInception to 2014 | 42 trials37 included in meta-analysisN=18,097 (8,466 EFV vs. 9,631 other) | Randomized trials and quasirandomized trialsMean study N: 303 (range, 47 to 1,771)Mean study duration: 78 weeks (range, 12 to 280 weeks) | HIV+ adults and children (although no pediatric trials met inclusion criteria)No geographical restrictions | EFV vs. other regimens as first-line therapy | Two authors received funding from various pharmaceutical companies; the other authors report no funding or conflicts of interest | Fair |

**Abbreviations:** ABC=abacavir; CD4=cluster of differentiation 4; EFV=efavirenz; RCT=randomized, controlled trial, U.S.=United States.